eurofins scientific se - ERFSF

ERFSF

Close Chg Chg %
59.01 -1.68 -2.85%

Open Market

57.33

-1.68 (2.85%)

Volume: 394.00

Last Updated:

Apr 16, 2025, 3:19 PM EDT

Company Overview: eurofins scientific se - ERFSF

ERFSF Key Data

Open

$56.23

Day Range

56.23 - 58.79

52 Week Range

44.61 - 68.45

Market Cap

$9.97B

Shares Outstanding

175.96M

Public Float

112.39M

Beta

0.74

Rev. Per Employee

N/A

P/E Ratio

24.57

EPS

$0.54

Yield

95.42%

Dividend

$0.54

EX-DIVIDEND DATE

Jul 3, 2024

SHORT INTEREST

N/A

AVERAGE VOLUME

1.88K

 

ERFSF Performance

1 Week
 
7.83%
 
1 Month
 
6.17%
 
3 Months
 
15.83%
 
1 Year
 
-11.47%
 
5 Years
 
6.16%
 

ERFSF Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings
Full Ratings ➔

About eurofins scientific se - ERFSF

Eurofins Scientific SE engages in the bio-analytical testing of food, environment, and pharmaceuticals products. The firm offers testing and laboratory services for agro science, genomics, discovery pharmacology and for supporting clinical studies. It operates through the following geographical segments: Europe, North America, and Rest of the World. The company was founded by Gilles G. Martin in 1987 and is headquartered in Luxembourg.

ERFSF At a Glance

Eurofins Scientific SE
23 Val Fleuri
Luxembourg, Luxembourg 1526
Phone 352-26-18-53-20 Revenue 7.52B
Industry Miscellaneous Commercial Services Net Income 439.60M
Sector Commercial Services 2024 Sales Growth 6.756%
Fiscal Year-end 12 / 2025 Employees 62,696
View SEC Filings

ERFSF Valuation

P/E Current 24.573
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 22.139
Price to Sales Ratio 1.321
Price to Book Ratio 2.123
Price to Cash Flow Ratio 7.50
Enterprise Value to EBITDA 9.239
Enterprise Value to Sales 1.878
Total Debt to Enterprise Value 0.338

ERFSF Efficiency

Revenue/Employee 119,925.234
Income Per Employee 7,011.598
Receivables Turnover 4.513
Total Asset Turnover 0.645

ERFSF Liquidity

Current Ratio 1.162
Quick Ratio 1.095
Cash Ratio 0.291

ERFSF Profitability

Gross Margin 11.423
Operating Margin 10.375
Pretax Margin 7.892
Net Margin 5.847
Return on Assets 3.773
Return on Equity 9.772
Return on Total Capital 4.744
Return on Invested Capital 4.87

ERFSF Capital Structure

Total Debt to Total Equity 106.253
Total Debt to Total Capital 51.516
Total Debt to Total Assets 42.341
Long-Term Debt to Equity 95.218
Long-Term Debt to Total Capital 46.166
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Eurofins Scientific Se - ERFSF

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
7.94B 7.05B 7.04B 7.52B
Sales Growth
+28.07% -11.16% -0.16% +6.76%
Cost of Goods Sold (COGS) incl D&A
6.34B 6.19B 6.37B 6.66B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
620.78M 638.15M 718.19M 747.88M
Depreciation
465.46M 468.52M 543.04M 570.16M
Amortization of Intangibles
155.31M 169.63M 175.14M 177.72M
COGS Growth
+21.97% -2.41% +2.98% +4.51%
Gross Income
1.60B 866.32M 670.72M 858.86M
Gross Income Growth
+59.74% -45.83% -22.58% +28.05%
Gross Profit Margin
+20.14% +12.28% +9.52% +11.42%
2021 2022 2023 2024 5-year trend
SG&A Expense
71.27M 41.41M 79.57M 73.34M
Research & Development
- - - -
-
Other SG&A
71.27M 41.41M 79.57M 73.34M
SGA Growth
+63.67% -41.90% +92.16% -7.83%
Other Operating Expense
- - - 5.41M
-
Unusual Expense
40.90M 11.14M 16.65M 11.79M
EBIT after Unusual Expense
1.49B 813.77M 574.50M 768.32M
Non Operating Income/Expense
(36.52M) 97.85M 11.03M (21.63M)
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
204.01M 92.80M 128.33M 153.28M
Interest Expense Growth
+86.42% -54.51% +38.28% +19.44%
Gross Interest Expense
204.01M 92.80M 128.33M 153.28M
Interest Capitalized
- - - -
-
Pretax Income
1.25B 818.81M 457.20M 593.42M
Pretax Income Growth
+57.85% -34.31% -44.16% +29.79%
Pretax Margin
+15.70% +11.61% +6.49% +7.89%
Income Tax
323.39M 183.08M 124.87M 155.87M
Income Tax - Current - Domestic
354.48M 211.46M 169.63M 194.70M
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
(31.09M) (28.38M) (44.76M) (38.83M)
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
925.49M 636.68M 332.77M 438.63M
Minority Interest Expense
472.79K (4.62M) (2.70M) (973.52K)
Net Income
925.02M 641.30M 335.47M 439.60M
Net Income Growth
+50.43% -30.67% -47.69% +31.04%
Net Margin Growth
+11.65% +9.09% +4.76% +5.85%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
925.02M 641.30M 335.47M 439.60M
Preferred Dividends
- - - -
-
Net Income Available to Common
925.02M 641.30M 335.36M 439.60M
EPS (Basic)
4.8304 3.3315 1.7385 2.3064
EPS (Basic) Growth
+46.27% -31.03% -47.82% +32.67%
Basic Shares Outstanding
191.50M 192.50M 192.90M 190.60M
EPS (Diluted)
4.6113 3.2226 1.6946 2.2601
EPS (Diluted) Growth
+46.91% -30.12% -47.42% +33.37%
Diluted Shares Outstanding
200.60M 199.00M 197.90M 194.50M
EBITDA
2.15B 1.46B 1.31B 1.53B
EBITDA Growth
+41.26% -31.91% -10.51% +16.70%
EBITDA Margin
+27.06% +20.74% +18.59% +20.32%

Eurofins Scientific Se in the News